PIK3CA and breast cancer: This observation is relevant as clinical trials such as BELLE [42, 43] and SOLAR1 established PI3K inhibitors like Alpelisib as effective therapies for PIK3CA-mutant BC, with regulatory approval in combination with fulvestrant [7] or nab-paclitaxel [44].